{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:56:39Z","timestamp":1788976599857,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1136\/ijgc-2022-004026","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T11:55:26Z","timestamp":1675770926000},"page":"504-513","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer"],"prefix":"10.1016","volume":"33","clinical-trial-number":[{"clinical-trial-number":"nct05173987","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05173987","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05173987","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Breana L","family":"Hill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryon P","family":"Graf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Danziger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas I","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Quintanilha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Haberberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro D","family":"Santin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Slomovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia A","family":"Elvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramez N","family":"Eskander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2022-004026_bb0010","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1136\/ijgc-2022-004026_bb0015","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1136\/ijgc-2022-004026_bb0020","first-page":"1","article-title":"A review of immune checkpoint blockade therapy in endometrial cancer","volume":"40","author":"Green","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1136\/ijgc-2022-004026_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13081900","article-title":"Histopathologic, genetic and molecular characterization of endometrial cancer racial disparity","volume":"13","author":"Javadian","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1136\/ijgc-2022-004026_bb0030","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-021-00301-z","article-title":"Immunotherapy in endometrial cancer: rationale, practice and perspectives","volume":"9","author":"Cao","year":"2021","journal-title":"Biomark Res"},{"key":"10.1136\/ijgc-2022-004026_bb0035","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ygyno.2021.12.030","article-title":"Molecular analysis of endometrial serous carcinoma reveals distinct clinicopathologic and genomic subgroups","volume":"164","author":"Lin","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-004026_bb0040","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/his.14015","article-title":"Incorporation of molecular characteristics into endometrial cancer management","volume":"76","author":"Vermij","year":"2020","journal-title":"Histopathology"},{"key":"10.1136\/ijgc-2022-004026_bb0045","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41379-021-00918-3","article-title":"An unusual phenotype occurs in 15 % of mismatch repair-deficient tumors and is associated with non-colorectal cancers and genetic syndromes","volume":"35","author":"Jaffrelot","year":"2022","journal-title":"Mod Pathol"},{"key":"10.1136\/ijgc-2022-004026_bb0050","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ygyno.2018.10.012","article-title":"Discordant loss of mismatch repair proteins in advanced endometrial endometrioid carcinoma compared to paired primary uterine tumors","volume":"151","author":"Ta","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-004026_bb0055","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-99364-z","article-title":"Concordance analysis of microsatellite instability status between polymerase chain reaction based testing and next generation sequencing for solid tumors","volume":"11","author":"Shimozaki","year":"2021","journal-title":"Sci Rep"},{"key":"10.1136\/ijgc-2022-004026_bb0060","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.20.01076","article-title":"Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG oncology\/GOG0209)","volume":"38","author":"Miller","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-004026_bb0065","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2022-004026_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-004026_bb0075","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1001\/jamaoncol.2020.4515","article-title":"Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial","volume":"6","author":"Oaknin","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1136\/ijgc-2022-004026_bb0080","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1200\/JCO.19.00818","article-title":"Nivolumab is effective in mismatch repair-deficient noncolorectal cancers: results from arm Z1D-A subprotocol of the NCI-MATCH (EAY131) study","volume":"38","author":"Azad","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-004026_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/cells10081878","article-title":"Evaluation of micro satellite instability and mismatch repair status in different solid tumors: a multicenter analysis in a real world setting","volume":"10","author":"Malapelle","year":"2021","journal-title":"Cells"},{"key":"10.1136\/ijgc-2022-004026_bb0090","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1158\/2767-9764.CRC-22-0161","article-title":"Real-World validation of TMB and microsatellite instability as predictive biomarkers of immune checkpoint inhibitor effectiveness in advanced gastroesophageal cancer","volume":"2","author":"Graf","year":"2022","journal-title":"Cancer Research Communications"},{"key":"10.1136\/ijgc-2022-004026_bb0095","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1001\/jama.2019.3241","article-title":"Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a clinicogenomic database","volume":"321","author":"Singal","year":"2019","journal-title":"JAMA"},{"key":"10.1136\/ijgc-2022-004026_bb0100","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1136\/ijgc-2022-004026_bb0105","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"10.1136\/ijgc-2022-004026_bb0110","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jmoldx.2019.06.011","article-title":"A novel next-generation sequencing approach to detecting microsatellite instability and pan-tumor characterization of 1000 microsatellite instability-high cases in 67,000 patient samples","volume":"21","author":"Trabucco","year":"2019","journal-title":"J Mol Diagn"},{"key":"10.1136\/ijgc-2022-004026_bb0115","author":"Foundation Medicine I","year":"2022","journal-title":"SUMMARY OF SAFETY AND EFFECTIVENESS DATA (SSED)"},{"key":"10.1136\/ijgc-2022-004026_bb0120","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1002\/cncr.32383","article-title":"Real-World progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer","volume":"125","author":"Khozin","year":"2019","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2022-004026_bb0125","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1002\/sim.9136","article-title":"Penalized regression for left-truncated and right-censored survival data","volume":"40","author":"McGough","year":"2021","journal-title":"Stat Med"},{"key":"10.1136\/ijgc-2022-004026_bb0130","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaoncol.2021.5153","article-title":"Implications of selection bias due to delayed study entry in clinical genomic studies","volume":"8","author":"Brown","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1136\/ijgc-2022-004026_bb0135","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/1475-6773.13669","article-title":"Validation analysis of a composite real\u2010world mortality endpoint for patients with cancer in the united states","volume":"56","author":"Zhang","year":"2021","journal-title":"Health Serv Res"},{"key":"10.1136\/ijgc-2022-004026_bb0140","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/j.1524-4733.2009.00600.x","volume":"12","author":"Berger","year":"2009","journal-title":"Value Health"},{"key":"10.1136\/ijgc-2022-004026_bb0145","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/aje\/kwr143","article-title":"Performance of disease risk scores, propensity scores, and traditional multivariable outcome regression in the presence of multiple confounders","volume":"174","author":"Arbogast","year":"2011","journal-title":"Am J Epidemiol"},{"key":"10.1136\/ijgc-2022-004026_bb0150","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.eururo.2019.08.020","article-title":"Clinical utility of the nuclear-localized AR-V7 biomarker in circulating tumor cells in improving physician treatment choice in castration-resistant prostate cancer","volume":"77","author":"Graf","year":"2020","journal-title":"Eur Urol"},{"key":"10.1136\/ijgc-2022-004026_bb0155","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-11-13","article-title":"One statistical test is sufficient for assessing new predictive markers","volume":"11","author":"Vickers","year":"2011","journal-title":"BMC Med Res Methodol"},{"key":"10.1136\/ijgc-2022-004026_bb0160","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1200\/JCO.21.01874","article-title":"Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study","volume":"40","author":"O\u2019Malley","year":"2022","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1136\/ijgc-2022-004026_bb0165","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1200\/JCO.2019.37.15_suppl.5501","article-title":"Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: the phase II PHAEDRA trial (ANZGOG1601)","volume":"37","author":"Antill","year":"2019","journal-title":"JCO"},{"key":"10.1136\/ijgc-2022-004026_bb0170","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1200\/JCO.19.01021","article-title":"Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent\/persistent endometrial cancer","volume":"37","author":"Konstantinopoulos","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-004026_bb0175","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.5858\/arpa.2021-0632-CP","article-title":"Mismatch repair and microsatellite instability testing for immune checkpoint inhibitor therapy: guideline from the College of American pathologists in collaboration with the association for molecular pathology and fight colorectal cancer","volume":"146","author":"Bartley","year":"2022","journal-title":"Arch Pathol Lab Med"},{"issue":"16_suppl","key":"10.1136\/ijgc-2022-004026_bb0180","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS5623","article-title":"KEYNOTE-C93\/GOG-3064\/ENGOT-en15: a phase 3, randomized, open-label study of first-line pembrolizumab versus platinum-doublet chemotherapy in mismatch repair deficient advanced or recurrent endometrial carcinoma","volume":"40","author":"Slomovitz","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-004026_bb0185","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.annonc.2021.09.016","article-title":"Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the friends of cancer research TMB harmonization project","volume":"32","author":"Vega","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2022-004026_bb0190","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S1470-2045(21)00064-4","article-title":"Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial","volume":"22","author":"Andre","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2022-004026_bb0195","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24024368?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24024368?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2022-004026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:29:35Z","timestamp":1753234175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24024368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1048891X24024368"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2022-004026","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2022-004026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/.","name":"copyright","label":"Copyright"}]}}